Identification of differential polypharmacology between the PARP inhibitor rucaparib and its major metabolite
H. Hu, C. Serra, A. Llebaria, A. A. Antolin
This study identifies differential polypharmacology between rucaparib and its metabolite M324, showing distinct kinase inhibition profiles with potential clinical implications.
bioRxiv · Nov 22, 2022 · PreprintPharmacology & Toxicology